1. Fischemister R, Castro L, Abi-Gerges A, Rochais F, Jurevicius J. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006; 99:816-828.
2. Maurice DH, Palmer D, Tilley D, Raymond DR and Jimmo SL. Cyclic nucleotide phosphodiesterase activity, expression and targeting in cells of the cardiovascular system. Mol Pharmacol 2003; 64:533-536.
3. Lin C, Xin ZC, Lin G and Lue TF. Phosphodiesterases as therapeutic targets. Urol 2003; 61:685-691.
4. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 2012; 165: 1288–1305.
5. Knight WE, Yan C. Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. Horm Metab Res 2012; 44: 766-75.
6. Zausig YA, Stowe DF, Zink W, Martin E. A comparison of three phosphodiesterase type3 inhibitors on mechanical and metabolic function in guinea pig isolated hearts. Anesth Analog 2006; 102:1646-52.
7. Yano M, Kohno M, Ohkusa T, Mochizuki M, Yamada J, Yukihisaoka T, Tanigava T, Matsuzaki M. Effect of milrinone on left ventricular relaxation and Ca2+ uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 2000; 279:1898-1905.
8. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Yukio, Hidaka H. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000; 59:347-356.
9. Mansouri MT, Shafiee-Nick R, Parsaee H, Seyedi M, Saberi MR, Sadeghian H. Inotropic and chronotropic effects of 6-hydroxy-4-methylquinolinone-2 (1H)-one derivatives in isolated rat atria. Iran Biomed J2007; 12:77-84.
10. Sadeghian H, Seyedi M, Saberi MR, Shafiee –Nik R, Hosseini A, Mansouri M, Parsaee H. Design, synthesis and pharmacological evaluation of 6-hydroxy-4-methylquinolin-2 (1H)-one derivatives as inotropic agents. J Enzyme Inhibit Med Chem 2008; 24:918-929.
11. Marín J, Hernández J. Diazepam potentiates the effects of endogenous catecholamines on contractility and cyclic AMP levels in rat ventricular myocardium. Naunyn Schmiedebergs Arch Pharmacol 2002; 365:260-8.
12. Fossa P, Menozzi G, Dorigo P, Floreanib M, Mosti L. Synthesis and pharmacological characterization of functionalized 2-pyridones structurally related to the cardiotonic agent milrinone. Bioorg Med Chem 2003; 11:4749-4759.
13. Bassani RA, Bassani WM. Reduced isolated responsiveness to adrenaline rat atria exposed to hyperosmotic solutions. Gen Pharmacol 1991; 22:151-157.
14. Vandecasteele G, Rochais F, Abi-Gerges A, Fischmeister R. Functional localization of cAMP signalling in cardiac myocytes. Biochem Soc Trans 2006; 34:484-8.
15. Lissandron V, Zaccolo M. Compartmentalized cAMP/PKA signaling regulates cardiac excitation-contraction coupling. J Muscle Res Cell Motil 2006; 27:399-403.
16. Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC 8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 1987; 240: 657-662.
17. Momose Y, Sasayama S. Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes. Cardiovasc Drugs Ther 1990; 4:713-718.
18. Mori T, Yamashita S, Hosokawa T, Yabuuchi Y. Cardiovascular effects of OPC-8490, a new positive inotropic agent with vasodilator action. Jpn J Pharmacol 1988; 46:130.
19. Joung B, Ogawa M, Lin SF, Chen P. The calcium and voltage clocks in sinoatrial node automaticity. K C J 2009; 39:217-222.
20. Korzick DH. Regulation of cardiac excitation-contraction coupling: a cellular update. Advance Physiol Edu 2003; 27:192-200.
21. Galindo-Tovar A, Vargas ML, Kaumann AJ. Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (−)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium. Naunyn-Schmied Arch Pharmacol 2009; 379:379–384.
22. Kaumann AJ, Galindo-Tovar A, Escudero E, Vargas ML. Phosphodiesterases do not limit β1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1–5 in rats. Naunyn-Schmied Arch Pharmacol 2009; 380:421–430
23. Juan-Fita MJ, Vargas ML, Henandez J. Comparative actions of diazepam and other phosphodiesterase
inhibitors on the effects of noradrenaline in rat myocardium. Pharmacol Toxicol 2003; 93:23-28.
24. Murthy KS, Zhou H, Makhlouf GM. PKA-dependent activation of PDE3A and PDE4 and inhibition of Adenylyl cyclase V/VI in smooth muscle. Am J Physiol Cell 2001; 282:508-517.
25. Vinogradova TM, Sirenko S, Lyashkove AE, Younes A, Li Y, Yang D, Lakatta EG. Constitutive phosphodiesterase activity restricts spontaneous beating rate of cardiac pacemaker cells by suppressing local Ca2+ releases. Circ Res 2008; 102:761-769.